Treatment of psychiatric disturbances in hypokinetic movement disorders
- 2 July 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 19 (10) , 965-981
Abstract
Introduction: We reviewed studies that assessed the treatment of psychiatric disturbances in Parkinson’s disease and atypical parkinsonisms. Neuropsychiatric disturbances in these conditions are frequent and have a profound impact on quality of life of patients and of their caregivers. It is therefore important to be familiar with the appropriate pharmacological and non-pharmacological interventions for treating these disorders. Areas covered: The authors searched for papers in English in Pubmed using the following keywords: Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, Lewy body dementia, depression, apathy, anxiety, fatigue, sleep disorders, obsessive compulsive disorders, psychosis, hallucinations, delusions, impulse control disorders. Expert opinion: In Parkinson’s disease, depression may benefit from the optimization of dopaminergic therapy, from the use of antidepressants acting on both the serotoninergic and noradrenergic pathways and from cognitive behavioral therapy. Psychosis in Parkinson’s disease may improve with the use of clozapine; the serotonin inverse agonist pimavanserin has been shown to be effective. Treatment of impulse control disorders is primarily based on the removal of dopamine agonists. No controlled studies have investigated the treatment of neuropsychiatric disorders in multiple system atrophy, progressive supranuclear palsy or corticobasal degeneration. Acethylcholinesterase inhibitors may be used to treat hallucinations in Lewy body dementia.Keywords
Funding Information
- not funded
This publication has 202 references indexed in Scilit:
- Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s diseaseChinese Medicine, 2013
- Caffeine for treatment of Parkinson diseaseNeurology, 2012
- A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseaseNeurology, 2012
- Effects of STN and GPi Deep Brain Stimulation on Impulse Control Disorders and Dopamine Dysregulation SyndromePLOS ONE, 2012
- Telephone-Based Cognitive–Behavioral Therapy for Depression in Parkinson DiseaseJournal of Geriatric Psychiatry and Neurology, 2011
- Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placeboMovement Disorders, 2010
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease PsychosisNeuropsychopharmacology, 2009
- Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE TrialAnnals of Neurology, 2009
- Fatigue in levodopa-naïve subjects with Parkinson diseaseNeurology, 2008
- Manic behaviour induced by deep-brain stimulation in Parkinson's disease: evidence of substantia nigra implication?Journal of Neurology, Neurosurgery & Psychiatry, 2006